Longitudinal profiling of IDH-mutant astrocytomas reveals acquired RAS-MAPK pathway mutations associated with inferior survival
Open Access
- 6 January 2025
- journal article
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 7 (1) , vdaf024
Abstract
Background: Isocitrate dehydrogenase (IDH)-mutant astrocytomas represent the most frequent primary intraparenchymal brain tumor in young adults, which typically arise as low-grade neoplasms that often progress and transform to higher grade despite current therapeutic approaches. However, the genetic alterations underlying high-grade transformation and disease progression of IDH-mutant astrocytomas remain inadequately defined. Methods: Genomic profiling was performed on 205 IDH-mutant astrocytomas from 172 patients from both initial treatment-naive and recurrent post-treatment tumor specimens. Molecular findings were integrated with clinical outcomes and pathologic features to define the associations of novel genetic alterations in the RAS-MAPK signaling pathway. Results: Likely oncogenic alterations within the RAS-MAPK mitogenic signaling pathway were identified in 13% of IDH-mutant astrocytomas, which involved the KRAS, NRAS, BRAF, NF1, SPRED1, and LZTR1 genes. These included focal amplifications and known activating mutations in oncogenic components (e.g. KRAS, BRAF), as well as deletions and truncating mutations in negative regulatory components (e.g. NF1, SPRED1). These RAS-MAPK pathway alterations were enriched in recurrent tumors and occurred nearly always in high-grade tumors, often co-occurring with CDKN2A homozygous deletion. Patients whose IDH-mutant astrocytomas harbored these oncogenic RAS-MAPK pathway alterations had inferior survival compared to those with RAS-MAPK wild-type tumors. Conclusions: These findings highlight novel genetic perturbations in the RAS-MAPK pathway as a likely mechanism contributing to the high-grade transformation and treatment resistance of IDH-mutant astrocytomas that may be a potential therapeutic target for affected patients and used for future risk stratification.Keywords
Funding Information
- UCSF Glioblastoma Precision Medicine Program
- The Sandler Foundation
- Helen Diller Family Comprehensive Cancer Center Molecular Oncology Program Award.
- Gilbert Family Foundation
- Morgan Adams Foundation
- Ross Family
- UCSF Department of Pathology Experimental Neuropathology Endowment Fund
- UCSF Program for Breakthrough Biomedical Research
- UCSF Brain Tumor SPORE (P50 CA097257)
This publication has 61 references indexed in Scilit:
- Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent GliomaScience, 2014
- MSIsensor: microsatellite instability detection using paired tumor-normal sequence dataBioinformatics, 2013
- Signatures of mutational processes in human cancerNature, 2013
- PDGFRA Amplification is Common in Pediatric and Adult High‐Grade Astrocytomas and Identifies a Poor Prognostic Group in IDH1 Mutant GlioblastomaBrain Pathology, 2013
- Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutationsActa Neuropathologica, 2012
- IDH1 mutation is sufficient to establish the glioma hypermethylator phenotypeNature, 2012
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarateNature, 2009
- IDH1 Mutations Are Early Events in the Development of Astrocytomas and OligodendrogliomasThe American Journal of Pathology, 2009
- Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1–like phenotypeNature Genetics, 2007